^
CANCER:

Small Intestinal Carcinoma

NTRK3 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
gemcitabine + docetaxel
Sensitive: A2 - Guideline
NTRK1 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive: A2 - Guideline
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
LV5FU2
Sensitive: A2 - Guideline
MSI-H/dMMR
Small Intestinal Carcinoma
nivolumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Small Intestinal Carcinoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
FOLFOX
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
CAPOX
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
bevacizumab
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
capecitabine
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
irinotecan
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
FOLFIRI
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
docetaxel
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
paclitaxel + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
carboplatin + paclitaxel
Sensitive: A2 - Guideline
NTRK1 fusion
Small Intestinal Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Small Intestinal Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Small Intestinal Carcinoma
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
GTX
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
FOLFOXIRI
Sensitive: A2 - Guideline
No biomarker
Small Intestinal Carcinoma
mFOLFOX6
Sensitive: A2 - Guideline
MSI-L/dMMR
Small Intestinal Carcinoma
dostarlimab
Sensitive: A2 - Guideline
RET fusion
Small Intestinal Carcinoma
selpercatinib
Sensitive: C1 - Off-label
PTEN mutation + MSI-H/dMMR
Small Intestinal Carcinoma
PD1 inhibitor
Resistant: C3 – Early Trials
dMMR/MSI-H + TMB-L
Small Intestinal Carcinoma
PD1 inhibitor
Resistant: C3 – Early Trials
VEGFA overexpression
Small Intestinal Carcinoma
bevacizumab
Sensitive: C3 – Early Trials
MSI-H/dMMR + TMB-H + PD-L1 overexpression
Small Intestinal Carcinoma
nivolumab + ipilimumab
Sensitive: C4 – Case Studies